FUT vs FUE Hair Transplant?

If you were to get a hair transplant, would you pick FUE or FUT? Another name for FUT is strip hair transplants. FUE is a more recent hair restoration technology.

What is the Difference Between FUE and FUT?

  1. Follicular Unit Extraction (FUE) scars are small, round and numerous. In contrast, Follicular Unit Transplantation (FUT) strip scars are linear and can stretch or remain minimally visible.
  2. FUE procedures typically take a much longer time than FUT procedures.
  3. FUE is more expensive than FUT on a per graft basis.
  4. In most cases, FUE surgeries involve fewer grafts than FUT surgeries.

It has been a while since the last poll.  Today there are two of them, and both are related to hair transplants: the best currently available option to treat hair loss in both men and women. The first poll below can be taken by both men and women. However, the second one is only applicable to men as far as I know. Only two options for each answer.

Please closely read all the options in the below poll before voting. You can only vote once, and cannot edit your vote.

Poll: FUE or FUT Hair Transplant?

A total of 1756 people responded, with 1,536 picking FUE and 220 picking FUT. Most people clearly seem to prefer FUE versus FUT.

FUE or FUT Hair Transplants.


Would you Ever Get a FUE Body Hair Transplant (BHT) ?

A lot of FUE procedures now include some body hair that is moved from the body to the scalp. Such procedures are known as body hair transplants (BHT). Would you get such a surgery?

Total responses = 1,854.

YES = 909 (49.0%).

NO = 945 (51.0%).

So its Shiseido/Replicel versus RIKEN/Tsuji in Kobe

Update: And in other important news from Japan from this week:

— Dr. Tsuji published a new paper several days ago.

— Pokemon Go was finally launched in Japan, its spiritual homeland.

Without any doubt, there has never been a better year than this one in the hair loss research world. The last four months have been especially fruitful, and I am not even considering a number of newer entrants in the field (just because most seem suspicious or are likely to produce best case results that will be akin to those from Rogaine). Key noteworthy recent developments:

  • First, in April, Follica (which had been left for dead by many due to its numerous conflicting signals since inception in 2006) surprised us and is clearly alive and aims to release its product in 2018 in a best case scenario. The company’s majority owner PureTech stated in a summary document that “skin disruption alone was safe and generates new follicles as well as new hair“.
  • Thereafter, in June, Aclaris Therapeutics’ CEO Mr. Neal Walker clearly stated at three difference investor presentation that “topical covalently bound highly selective JAK3 inhibitors” work in treating androgenetic alopecia and not just in treating alopecia areata. Alcaris will be conducting trials on this use of JAK inhibitors in 2017.
  • Also in June, Histogen made a surprising announcement that it would start treating patients in Mexico in 2018. Like Follica, many people had left Histogen for dead due to the fact that the company has been involved in hair loss research for a similarly lengthy period of time with mixed signals in terms of efficacy, clinical trial and product release dates.
  • Then, in July came perhaps the most exciting news ever in the hair loss cure research world. RIKEN/Dr. Takashi Tsuji, Kyocera and Organ Technologies have formed a partnership that aims to commercially release a product in 2020 that will essentially represent a cure for hair loss. 2020 is clearly a best case scenario assuming no major hiccups along the way. Mr. Tsuji is a world renowned and extremely well respected and modest scientist; RIKEN has access to Japanese government funds and to numerous leading scientists in the world of regenerative medicine; Kyocera is a private sector multinational behemoth with pre-existing hardware side technology and expertise that will likely be of much use to Dr. Tsuji.
  • And finally, today the Shiseido/Replicel team finally announced the commencement of delayed clinical trials in Japan (see bottom part of this post).

RIKEN and Dr. Tsuji are conducting their research at the Kobe Biomedical Innovation Cluster (KBIC) in Japan in RIKEN’s Integrated Innovation Building.

RIKEN Integrated Innovation Building
RIKEN Integrated Innovation Building.

Shiseido/Replicel Joins Kyocera/RIKEN/ Tsuji at the KBIC

Today, in yet one more major positive development this year, it was announced that the Shiseido/Replicel team has finally started its delayed 60-person (men and women included) Japanese clinical trials for its autologous cell therapy based RCH-01 product.

Riken Kobe Business Center
Riken Kobe Business Center.

While the study will be conducted at two hospitals in Tokyo, the injected product(s) will be manufactured by Shiseido at their SPEC (Cell-Processing and Expansion Center) in KBIC. I discussed this facility in a post in 2014. It is located in the Business Support Center for Biomedical Research Activities (BMA) building in KBIC.

So Shiseido and RIKEN’s respective research and development work will be conducted at buildings within a mile of each other!! 

I arrived at this conclusion after analyzing this map (both buildings are on the right side of the railroad).

While doing research on KBIC, I found that it is located on Port Island in the city of Kobe, and Port Island is an artificially constructed island. Would be quite something if humans end up creating new replacement hair follicles on a man-made island.